| Document and Entity Information | Feb. 23, 2021 |
| Cover [Abstract] | |
| Entity Registrant Name | MERIDIAN BIOSCIENCE INC |
| Amendment Flag | true |
| Entity Central Index Key | 0000794172 |
| Document Type | 8-K/A |
| Document Period End Date | Feb. 23, 2021 |
| Entity Incorporation State Country Code | OH |
| Entity File Number | 0-14902 |
| Entity Tax Identification Number | 31-0888197 |
| Entity Address, Address Line One | 3471 River Hills Drive |
| Entity Address, City or Town | Cincinnati |
| Entity Address, State or Province | OH |
| Entity Address, Postal Zip Code | 45244 |
| City Area Code | (513) |
| Local Phone Number | 271-3700 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, no par value |
| Trading Symbol | VIVO |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Description | On the morning of February 23, 2021, Meridian Bioscience, Inc. (“Meridian” or the “Company”) issued a press release providing an update regarding its emergency use authorization request to the U.S. Food and Drug Administration with respect to its Revogene SARS-CoV-2 test (the “Original Release”) and filed a Form 8-K (the “Original Form 8-K”) which furnished as an exhibit a copy of the Original Release. This Amendment No. 1 to Form 8-K is being filed for the purpose of reporting a subsequent press release issued by Meridian on February 23, 2021 that corrects the Original Release. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated by reference herein. |
